Progensa™ PCA3 test for prostate cancer

• DOI: 10.1586/erm.10.122
• Publication Date: 2011-03-15T10:23:48Z
• Authors: Xavier Durand; Stephane Moutereau; Evanguelos Xylinas; Alexandre de la T...
• Keywords: Prostate biopsy

The lack of accuracy from typical prostate cancer diagnostic tools led us to investigate new biomarkers. Prostate gene 3 (PCA3 or DD3) is a promising urinary biomarker cancer. This specific noncoding mRNA highly overexpressed in more than 95% primary tumors. feasibility PCA3 gene-based molecular assay based on the detection cells urine has been demonstrated, and quantitative test with potential for general use clinical settings was developed; Progensa™ (Gen-Probe Inc., San Diego, CA, USA) test. Current data literature demonstrate superiority score over prostate-specific antigen, terms predictive value specificity, albeit slightly lower sensitivity. These results are particularly encouraging population patients who have first negative biopsy, as could avoid unnecessary repeated biopsies. Furthermore, limited investigated correlation between scores tumor volumes, well an ability distinguish indolent significant In near future, combinations multiple biomarkers integrating will optimize characterization